STAT

Opinion: Sexually transmitted infections are at an all-time high. Urgent action is needed

Clinicians and public health experts know how to prevent STIs. But the country has failed to implement basic public health practices to do that.
A billboard from the AIDS Healthcare Foundation warning of drug-resistant gonorrhea is seen on Sunset Boulevard in Hollywood, Calif. Nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the U.S. in 2017.

The Centers for Disease Control and Prevention reported Tuesday unprecedented year-after-year rises in rates of sexually transmitted infections (STIs) in the United States. As physicians who care for patients with these infections and who oversee public health responses to STI outbreaks, we, like many of our colleagues, are frustrated and challenged by the anemic responses to this escalating public health epidemic.

Our concerns are especially acute because the medical and public health communities know how to prevent these infections, yet as a country we have failed to implement basic public health practices that could reverse these trends.

STIs are at an . Nearly 2.3 million cases of chlamydia, — infants born with syphilis contracted from their undiagnosed and untreated mothers — more than doubled from 2013 to 2017. Congenital syphilis is especially worrisome because it can cause miscarriage, premature birth, stillbirth, or death of newborn babies.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks